Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | ROR1 | Q01973 | 6/20 | 0.47 |
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010219 | 0.84 | CSF1R (0.72) | CSF1RROR1ABL1 | |
| SCHEMBL12652639 | 0.84 | CSF1R (0.72) | CSF1RROR1ABL1 | |
| SCHEMBL24925257 | 0.79 | CSF1R (0.51) | CSF1RROR1ABL1RETKIT | |
| SCHEMBL24538489 | 0.75 | ABL1 (0.53) | CSF1RROR1ABL1RETKIT | |
| SCHEMBL29652093 | 0.75 | ABL1 (0.53) | CSF1RROR1ABL1RETKIT | |
| SCHEMBL26260034 | 0.72 | ABL1 (0.45) | CSF1RROR1ABL1KITDDR1 | |
| SCHEMBL15096062 | 0.71 | ROR1 (0.67) | CSF1RROR1ABL1RETKIT | |
| SCHEMBL29506341 | 0.71 | CSF1R (0.67) | CSF1RROR1ABL1 | |
| SCHEMBL27974670 | 0.71 | KIT (0.76) | KITDDR1 | |
| SCHEMBL24528541 | 0.71 | LCK (0.57) | CSF1RABL1KITDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192897-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210277012-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277012-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | CSF1R 4497/4885ROR1 2281/4885ABL1 362/4885 |
| US-11192897-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | CSF1R 4497/4885ROR1 2281/4885ABL1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.